NDAORALTABLET, FOR SUSPENSION
Approved
Jul 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
SPRITAM (levetiracetam) by Molecular Devices is 12. Approved for epilepsy, seizure disorders. First approved in 2015.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SPRITAM (levetiracetam) is an oral antiepileptic drug approved in 2015 that binds to the synaptic vesicle protein SV2A to regulate neurotransmitter release and prevent seizures. It is indicated for epilepsy and seizure disorders, with emerging evidence supporting use in neuropsychiatric conditions including anxiety, OCD, and PTSD, as well as neurodegenerative diseases. The precise mechanism remains incompletely understood, but SV2A interaction likely contributes to its anticonvulsant activity.
$0.001BPart D
Peak7.9 years to LOEProduct is at peak lifecycle with modest Part D spending, indicating stable but limited commercial expansion and likely smaller brand team relative to blockbuster competitors.
Mechanism of Action
12.1 Mechanism of Action The precise mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown. A saturable and stereoselective neuronal binding site in rat brain tissue has been described for levetiracetam. Experimental data indicate that this binding site is the synaptic…
Worked on SPRITAM at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.